ARCT insider transaction filings
Arcturus Therapeutics Holdings Inc. — 43 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-15. Screen ARCT transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for ARCT between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Arcturus Therapeutics Holdings Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-15 | 4 | Markels John — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Marantz Jing L. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Slaoui Moncef — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Marquet Magda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | HOLMES EDWARD W — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | BARLOW JAMES F — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | FARRELL PETER C — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2026-05-07 | 4 | MULROY DENNIS — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Roberts Joseph — Controller | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Kurata Lance — Chief Legal Officer | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Chivukula Pad — Chief Scientific Officer & COO | Grant/award (A): 54,000 (derivative) @ $0 | EDGAR |
| 2025-12-19 | 4 | Payne Joseph E — President and CEO, Director | Grant/award (A): 175,000 (derivative) @ $0 | EDGAR |
| 2025-08-20 | 4/A | SASSINE ANDY — Chief Financial Officer, Director | Purchase (P): 1,238 @ $16.56 | EDGAR |
| 2025-08-19 | 4 | SASSINE ANDY — Chief Financial Officer, Director | Purchase (P): 1,238 @ $16.56 | EDGAR |
| 2025-06-11 | 4 | Markels John — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Marantz Jing L. — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Slaoui Moncef — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | Marquet Magda — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | HOLMES EDWARD W — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | BARLOW JAMES F — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2025-06-11 | 4 | FARRELL PETER C — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Kurata Lance — Chief Legal Officer | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Chivukula Pad — Chief Scientific Officer & COO | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | Payne Joseph E — President and CEO, Director | Grant/award (A): 196,000 (derivative) @ $0 | EDGAR |
| 2024-12-18 | 4 | SASSINE ANDY — Chief Financial Officer, Director | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-10-16 | 4 | Chivukula Pad — Chief Scientific Officer & COO | Sale (S): 12,000 @ $20.76 | EDGAR |
| 2024-06-21 | 4 | Slaoui Moncef — Director | Grant/award (A): 15,000 (derivative) @ $0 · Grant/award (A): 14,794 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Marantz Jing L. — Director | Option exercise (M): 3,131 @ $0 · Option exercise (M): 3,131 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Markels John — Director | Option exercise (M): 3,131 @ $0 · Option exercise (M): 3,131 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Marquet Magda — Director | Option exercise (M): 3,131 @ $0 · Option exercise (M): 3,131 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | HOLMES EDWARD W — Director | Option exercise (M): 3,131 @ $0 · Option exercise (M): 3,131 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | BARLOW JAMES F — Director | Option exercise (M): 3,131 @ $0 · Option exercise (M): 3,131 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | FARRELL PETER C — Director | Option exercise (M): 3,131 @ $0 · Option exercise (M): 3,131 (derivative) @ $0 · Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | SASSINE ANDY — Chief Financial Officer, Director | Sale (S): 50,000 @ $32.03 | EDGAR |
| 2024-06-07 | 4 | Chivukula Pad — Chief Scientific Officer & COO | Sale (S): 114 @ $45 | EDGAR |
| 2024-06-04 | 4 | Chivukula Pad — Chief Scientific Officer & COO | Sale (S): 26,000 @ $40.01 | EDGAR |
| 2024-03-27 | 4 | Chivukula Pad — Chief Scientific Officer & COO | Sale (S): 17,435 @ $35.02 | EDGAR |
| 2024-03-21 | 4 | Chivukula Pad — Chief Scientific Officer & COO | Sale (S): 8,565 @ $35.01 | EDGAR |
| 2023-12-19 | 4 | Kurata Lance — Chief Legal Officer | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2023-12-19 | 4 | Kummerfeld Keith C — See Remarks | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2023-12-19 | 4 | Chivukula Pad — Chief Scientific Officer & COO | Grant/award (A): 125,000 (derivative) @ $0 | EDGAR |
| 2023-12-19 | 4 | Payne Joseph E — President and CEO, Director | Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2023-12-19 | 4 | SASSINE ANDY — Chief Financial Officer, Director | Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Arcturus Therapeutics Holdings Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-25 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-02 | 8-K | 1.01 — Entry into a Material Definitive Agreement 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-05 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-03 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-10 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-10-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ARCT returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →